SEC Form 4 · accession 0001104659-15-068859

KYTHERA BIOPHARMACEUTICALS INC · KYTH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 1, 2015

Accepted (ET)

Oct 2, 2015 · 2:17 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001436304

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Oct 1, 2015	D	1,872	—	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (right to buy)^F2	$1.35	Oct 1, 2015	D	18,908	D	—	Jan 23, 2018	Common Stock	18,908	D
Stock Option (right to buy)^F2	$6.58	Oct 1, 2015	D	5,672	D	—	Mar 15, 2021	Common Stock	5,672	D
Stock Option (right to buy)^F2	$8.22	Oct 1, 2015	D	5,672	D	—	Feb 1, 2022	Common Stock	5,672	D
Stock Option (right to buy)^F2	$16.00	Oct 1, 2015	D	5,672	D	—	Oct 10, 2022	Common Stock	5,672	D
Stock Option (right to buy)^F2	$21.65	Oct 1, 2015	D	6,618	D	—	Jun 4, 2023	Common Stock	6,618	D
Stock Option (right to buy)^F2	$33.26	Oct 1, 2015	D	8,400	D	—	Jun 5, 2024	Common Stock	8,400	D
Stock Option (right to buy)^F2	$53.26	Oct 1, 2015	D	11,591	D	—	Jun 2, 2025	Common Stock	11,591	D

F1Disposed of pursuant to the Amended and Restated Agreement and Plan of Merger dated as of August 4, 2015 (the "Merger Agreement"), by and among Allergan plc (formerly known as Actavis plc) ("Allergan"), Keto Merger Sub, Inc. (a wholly owned subsidiary of Allergan) and Issuer, whereby each share of Issuer common stock was canceled in exchange for $75.00 in cash, without interest.
F2Pursuant to the Merger Agreement, each option to purchase common stock was canceled and paid in cash assuming a stock price of $75.00.